Neurazon's Enhanced Whole Exome Sequencing Service

Whole Exome Sequencing (WES) is a comprehensive genetic test that identifies changes in a patient's DNA that are causative or related to their medical concerns. By focusing on the entire protein-coding regions of the genome – the exome – WES offers you the coverage you need to diagnose patients rapidly and reliably. Overcoming the Obstacles of Rare Disease Diagnostics with Neurazon With more than 7,000 identified rare diseases and approximately 80% being linked to genetic causes, diagnosing rare disease patients can often be difficult – resulting in lengthy, expensive, and emotional diagnostic odysseys.1,2 With WES, this doesn’t have to be the case. Containing the majority (~85%) of known disease-causing changes, WES uncovers the cause of rare diseases in less time and at a lower overall cost – leading to better patient outcomes. With Neurazon, we’ve taken WES to the next level. Enhanced to provide unparalleled clinical coverage and diagnostic power in a single test, our product design and medical interpretation utilize the world’s largest rare disease-centric Bio/Databank containing >31 million unique variants from over 120 countries. The Results: Diagnosing complex and unsolved patient cases – quicker and with the highest levels of certainty.